August 2012
-
GlaxoSmithKline has opened a new £56 million, 4500 m2 manufacturing facility for its Ellipta DPI products. According to GSK, the new facility will create 150 jobs and will double production of Ellipta inhalers at the… Read more . . .
-
Discovery Laboratories, which is developing Aerosurf aerosolized KL4 surfactant for the treatment of respiratory distress syndrome in premature infants, has changed its name to Windtree Therapeutics, the company said. CEO Craig Fraser, who was appointed… Read more . . .
-
Swedish CDMO Recipharm has announced that it will acquire Kemwell’s CDMO business, including North Carolina-based Cirrus Pharmaceuticals. Kemwell acquired Cirrus Pharmaceuticals, which offers OINDP development and manufacturing services, in 2013. In February 2016, Cirrus Pharmaceuticals… Read more . . .
-
The Medicon Valley Inhalation Consortium (MVIC) has announced the appointment of Lars Asking as VP as of May 1, 2016. Asking was most recently Principle Scientist at Novo Nordisk and previously developed inhaled products at… Read more . . .
-
Powder characterization specialist Freeman Technology has announced that its Chinese operations have moved into a larger facility equipped with a laboratory and that the company has hired Tom Qin as General Manager and Ruty Li… Read more . . .
-
Mast Therapeutics has announced that the Duke Clinical Research Institute will serve as the coordinating center for the Heart Failure Clinical Research Network (HFN) as it conducts a Phase 2 study of AIR001 sodium nitrite… Read more . . .
-
Quotient Clinical’s new GMP facility in Nottingham, UK will include added spray drying capacity for spray drying of batches up to 2 kilograms. The facility is scheduled to open later this year. Quotient Clinical’s inhaled… Read more . . .
-
Hovione has announced the launch of a new company called Hovione Technology, which “focuses on offering an inhaler that matches your product, your needs, your patients.” The company’s devices include the Twin Caps and PowdAir… Read more . . .
-
Raptor Pharmaceutical has launched Quinsair levofloxacin inhalation solution for the treatment of P. aeruginosa infections in cystic fibrosis patients in Germany and Denmark, the company said. According to Raptor, it plans to launch Quinsair in… Read more . . .
-
An analysis of data from Boehringer Ingelheim’s WISDOM study showed that withdrawal of ICS for COPD patients using the Spiriva Handihaler tiotropium bromide DPI plus salmeterol is associated with a higher exacerbation rate in patients… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland